Bridging Clinical Trial and Real-World Evidence in Retinal Diseases: Updated Strategies With Anti-VEGF Therapies

Please visit answersincme.com/BWG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ferhina Ali, MD, MPH, FASRS. In this activity, an expert in retinal diseases discusses integrating clinical trial and real-world evidence into the use of newer-generation anti–vascular endothelial growth factor (VEGF) agents. Upon completion of this activity, participants should be better able to: Review the role of different types of data in informing management of retinal diseases; Assess clinical trial data and real-world evidence supporting the use of newer-generation anti-VEGF agents for retinal diseases; and Propose treatment plans for the management of retinal diseases based on clinical trial data and real-world evidence.

Please visit answersincme.com/ADC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jordana Goren Fein, MD, MS. In this activity, an expert in retinal vein occlusion (RVO) reviews diagnostic best practices, newer-generation anti-VEGF therapies, and patient-centered management strategies. Upon completion of this activity, participants should be better able to: Describe best practices for diagnosing RVO; Differentiate between the clinical profiles of available newer-generation intravitreal anti-VEGF therapies for macular edema (ME) secondary to RVO; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.

Please visit answersincme.com/AGN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ferhina Ali, MD, MPH, FASRS. In this activity, an expert in retinal diseases discusses anti-VEGF treatment of diabetic macular edema. Upon completion of this activity, participants should be better able to: Recognize factors that contribute to patients' treatment burden with intravitreal anti–vascular endothelial growth factor (VEGF) therapies for diabetic macular edema (DME); Assess the clinical profiles of long-acting intravitreal anti-VEGF agents for DME; and Recommend individualized strategies to enhance long-term treatment outcomes for patients with DME.

Please visit answersincme.com/YMM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nitish Mehta, MD; and Sarwar Zahid, MD. In this activity, experts in diabetic retinopathy discuss long-acting anti-VEGF agents and strategies to improve outcomes for patients with diabetic macular edema (DME). Upon completion of this activity, participants should be better able to: Recognize factors that contribute to patients' treatment burden with intravitreal anti-VEGF therapies for diabetic macular edema (DME); Assess the clinical profiles of long-acting intravitreal anti-VEGF agents for DME; and Recommend individualized strategies to enhance long-term treatment outcomes for patients with DME.

Please visit answersincme.com/RTS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, a pediatrician and a pediatric dermatologist discuss strategies for optimizing biologic treatment for moderate to severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when treatment escalation to systemic therapy is warranted in pediatric patients with atopic dermatitis (AD); Select the optimal biologic for a given pediatric patient with moderate to severe AD; and Outline strategies to optimize biologic treatment in pediatric patients with moderate to severe AD. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/SYV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in retinal vein occlusion (RVO) discuss diagnosis and anti-VEGF treatment of the condition. Upon completion of this activity, participants should be better able to: Explain the rationale for exploring longer-acting anti-VEGF treatment for patients with RVO; Recognize the importance of early diagnosis to address the burden of RVO; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.

Please visit answersincme.com/XCG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. This educational activity brings together leading experts in ophthalmology and oncology to explore clinical strategies for managing ocular adverse events associated with a novel class of therapies for advanced breast cancer: the oral selective estrogen receptor degraders (SERDs). Faculty will share key insights and practical guidance on identifying and managing common ocular side effects—particularly photopsia and dry eye—with the goal of enhancing patient care and improving quality of life for individuals navigating survivorship with advanced breast cancer. Upon completion of this activity, participants should be better able to: Recognize the implications of using oral SERDs in HR-positive, HER2-negative breast cancer for ophthalmic practice; Describe the ocular toxicities associated with oral SERDs used in breast cancer treatment; and Apply multidisciplinary strategies to facilitate the detection and management of ocular toxicities in patients receiving oral SERDs.

Please visit answersincme.com/XWJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, a retina expert discusses the role of long-acting anti–vascular endothelial growth factor (VEGF) therapy in neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Recognize the rationale for long-acting anti-VEGF therapy in nAMD; Select the optimal long-acting anti-VEGF therapy for individual patients with nAMD; and Integrate practical strategies to enhance the clinical implementation of long-acting anti-VEGF therapy in patients with nAMD.

Please visit answersincme.com/GCB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of diabetic macular edema (DME) discuss the primary care physician (PCP) and ophthalmologist’s partnership in the care for patients with DME and optimizing treatment with VEGF-targeting agents. Upon completion of this activity, participants should be better able to: Explain how extending treatment intervals for DME can improve patient satisfaction and treatment persistence with intravitreal anti-VEGF therapy; Discuss the clinical benefits of longer-acting intravitreal anti-VEGF agents in the treatment of DME; Describe multidisciplinary care plans that improve the long-term treatment outcomes of patients with patients with DME; and Outline strategies for optimizing DME outcomes in the primary care setting. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.